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Genomics has come to dominate biomedical research in recent years. For exam-
ple, high-throughput genomic technologies have been used for the comprehensive
analysis of multiple myeloma (MM). In particular, gene expression profiling has
enabled the molecular classification of MM, which is widely used in biological
research.1 However, a knowledge of protein expression is essential for identifying
therapeutic targets, since proteins are the molecules through which most new
drugs achieve their efficacy. The limited amount of sample remaining after plasma
cell purification means that messenger RNA (mRNA) quantification is still used as
an indirect measure of protein expression in most cases. However, several studies
have shown that protein levels cannot be predicted from mRNA measurements.2
Immunohistochemistry and flow cytometry have been used to analyze expres-
sion at the protein level, although to a limited extent. These methods are of great
value and are of proven clinical utility, but they have some limitations that make
them less useful for studying intracellular protein levels. They mostly use directly
Protein analysis in bone marrow samples from patients with multiplemyeloma has been limited by the low concentration of proteinsobtained after CD138+ cell selection. A novel approach based on
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expression of multiple proteins extracted from CD138-purified multiple
myeloma samples frozen in RLT Plus buffer, which is commonly used for
nucleic acid preservation and isolation. Additionally, the biological and
clinical value of this analysis for a panel of 12 proteins essential to the
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of patients; mRNA levels were not associated with prognosis.
Interestingly, high levels of Cereblon and Ikaros proteins were associated
with longer progression-free survival only in patients who received
immunomodulatory drugs and not in those treated with other drugs. In
conclusion, the capillary nano-immunoassay platform provides a novel
opportunity for automated quantification of the expression of more than
20 proteins in CD138+ primary multiple myeloma samples. 
A novel nano-immunoassay method for 
quantification of proteins from CD138-purified
myeloma cells: biological and clinical utility
Irena Misiewicz-Krzeminska,1,2,3 Luis Antonio Corchete,1,2 Elizabeta A. Rojas,1,2
Joaquín Martínez-López,4 Ramón García-Sanz,1,2,5 Albert Oriol,7 Joan Bladé,8
Juan-José Lahuerta,6 Jesús San Miguel,9 María-Victoria Mateos1,2,5
and Norma C. Gutiérrez1,2,5
1Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain, 2Institute of Biomedical
Research of Salamanca (IBSAL), Spain; 3National Medicines Institute, Warsaw, Poland;
4Hematology Department, Hospital 12 de Octubre, CNIO, Complutense University,
CIBERONC, Madrid, Spain; 5Hospital Universitario de Salamanca, CIBERONC, Spain;
6Hospital 12 de Octubre, Madrid, Spain; 7Hospital Germans Trias i Pujol, Barcelona, Spain;
8Hospital Clinic, Barcelona, Spain and 9Clínica Universidad de Navarra, CIMA, IDISNA,
CIBERONC, Pamplona, Spain
ABSTRACT
marked antibodies that reduce the sensitivity of detection,
and fewer antibodies are available for these techniques,
even when used in an indirect assay.3
Immunohistochemistry allows only semiquantitative
analysis of protein expression, and requires a well-trained
pathologist to interpret the results. Moreover, neither
technique is able to identify non-specific antibody binding
to other proteins.3
Western blotting (WB) remains the “gold standard” tech-
nique for protein characterization in most laboratories.
However, WB consumes large quantities of reagents, has a
low throughput, and requires a great deal of time and
effort involving many laborious manual processing steps.
Moreover, WB only yields semiquantitative data of poor
repeatability, making it a challenge to go beyond using the
assay in discovery research to apply it reliably in the clin-
ical setting.4–6 A further drawback is that it is not always
possible to obtain the quantity of protein extract required
for WB from primary cancer samples. 
MM is a clear prototype of a bone marrow-infiltrating
tumor for which a relatively small quantity of sample is
available after the diagnostic procedure, which involves
morphological evaluation, immunophenotypic characteri-
zation by flow cytometry, and CD138+ plasma cell separa-
tion for routine fluorescence in situ hybridization analysis.
The recent development of a method based on the combi-
nation of capillary nano-electrophoresis with immunoas-
say (CNIA), also known as ‘simple western’, requires only
very small amounts of sample to be able to measure pro-
tein expression.3,7 This technical advance makes it possible
to analyze the expression of 50-100 proteins in a single
MM sample. Here we present the results of a pilot study
using this platform in MM patients. The main goal was to
quantify accurately and robustly the proteins extracted
from CD138-purified MM samples frozen in RLT Plus
buffer, which is commonly used as a method for RNA and
DNA preservation. Additionally, we attempted to estab-
lish the clinical value of this analysis using a panel of pro-
teins essential to MM pathogenesis, comparing it with
that of the corresponding RNA expression.  
Methods
For more specific information see the Online Supplementary File.
Patients and multiple myeloma cell lines
Sixty-three samples from patients diagnosed with MM
between October 2013 and November 2015 were included in the
study (Online Supplementary Table S1). Forty-three had been
enrolled in two Spanish Myeloma Group clinical trials: GEM2010
[bortezomib/melphalan/prednisone and lenalidomide/dexam-
ethasone in a sequential or alternating manner; (n=24)] and
BenVelPres [bendamustine/bortezomib/prednisone; (n=19)]. The
other 20 patients were not treated as part of a clinical trial. 
The impact of RNA and protein expression on patients’ survival
was evaluated only in the group of patients that took part in the
clinical trials (Online Supplementary Table S1). The scheme of the
study is presented in Figure 1. 
Protein extraction from RLT Plus buffer
Proteins were extracted by ice-cold acetone precipitation from
RNA-column flow-through liquid. To increase the rate of protein
precipitation 10 mM NaCl was added to the acetone at 80% (v/v).
For technical reasons, each sample was divided into two tubes and
extracted separately. After overnight incubation at -20ºC, the pro-
teins were centrifuged at 13,000 x g for 30 min at 4ºC, and washed
twice with 70% ice-cold ethanol followed by centrifugation for a
further 10 min. The protein precipitate was dried at 39ºC and dis-
solved with 50 μL 0.2 M NaOH for 10 min at room temperature
and 4x WB sample buffer for at least 15 min at room temperature.
Samples were then denatured at 95ºC for 5 min, cooled to room
temperature and stored in aliquots at -80ºC. Before any assay,
samples were heated to room temperature, then kept at 37ºC for
30 min in order to re-dissolve any protein that had precipitated
during freezing. 
Capillary electrophoresis immunoassay 
Capillary electrophoresis immunoassay or simple western
analysis was performed using the WESTM machine (ProteinSimple,
San Jose, CA, USA) in accordance with the manufacturer’s proto-
cols. The Total Protein Assay (ProteinSimple) was used to quantify
the protein concentration. In brief, 5 μL of proteins were loaded on
the plate, separated by size, labeled with a biotin reagent and
detected by chemiluminescence using streptavidin-horseradish
peroxidase. At the end of the run, the proportion of the protein of
interest in the total protein in the sample was measured, in com-
parison to a standard curve previously generated using JJN3 cell
line extracts of known protein concentrations.
Primary antibodies used in the study and the optimized condi-
tions for each antibody are presented in Table 1. Data were ana-
lyzed using CompassTM software. Each protein peak was meas-
ured automatically and normalized with respect to the GAPDH
median area under the peak. Expression of each protein is present-
ed as its abundance relative to GAPDH.
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Figure 1. Scheme of the study. 
DNA/RNA extraction and quantitative real-time 
polymerase chain reaction analysis
mRNA expression was evaluated by Taqman assay quantitative
real-time polymerase chain reaction (qRT-PCR) analysis using the
respective GAPDH Taqman assay as a control, by the 2-ΔCt method.  
Statistical analysis
Spearman correlations were calculated. Progression-free sur-
vival (PFS) was calculated for each gene and protein. Survival
curves were plotted using the Kaplan–Meier method and statisti-
cal significance was evaluated with the log-rank test.  
Results
Protein extraction from RLT Plus buffer results 
in optimal quality and quantity
Firstly, we evaluated the amount and quality of the pro-
tein extracted with our protocol. The data generated by
the WESTM system were visualized as virtual blots (Figure
2A) or peaks (Figure 2B) that were quantified as the area
under the curve using the inbuilt algorithm of the
CompassTM software. Using JJN3 myeloma cell line lysates
of known concentration, we generated a protein standard
curve that proved to be linear over the evaluated range of
concentrations (Figure 2C). The amount of protein
obtained from each sample ranged between 0.00 and 0.36
mg protein, with a median quantity of 0.06 mg per sam-
ple. Three of the 63 samples had insufficient material to
analyze protein expression (Figure 2D). We compared the
expression of the various proteins extracted from MM
cells stored in RLT Plus buffer with that obtained using the
standard RIPA protocol and found the signals to be similar
for the two protocols (Figure 2E,F). 
Optimization of protein quantification by capillary
nano-electrophoresis with immunoassay 
For each analyzed protein, we first searched in the
ProteinSimple antibody database for the optimized condi-
tions (http://www.proteinsimple.com/antibody/antibod-
ies.html). If the antibody was present, we re-evaluated it in
our system, using the antibody at the indicated concentra-
tion and at double and half the indicated concentration. In
the event that the protein evaluated was not present in the
database, we performed a full optimization, which consist-
ed of running the assays in the cell line samples at two con-
centrations (0.1 mg/mL and 0.2 mg/mL) with at least five
antibody dilutions in order to determine the optimal con-
centration at which the antigen-antibody binding was sat-
urated and no change in antibody concentration influenced
the result. The optimized concentrations for each anti-
body, the molecular weights at which the peaks were
observed, and the coefficients of variation arising from the
validation of each protein are shown in Table 1. 
Standard curves were produced for each protein to eval-
uate the range of linearity over which the expression of
each protein could be quantified. Briefly, each capillary
contained the sample at a different dilution, and the pro-
tein detection was visualized as virtual blots, as exempli-
fied by the use of Aiolos in Figure 3A. The peaks obtained
for each dilution, which were obtained automatically by
the program, have a distinct height and width, depending
on the sample dilution (Figure 3B). Once they had been
quantified the standard curve was generated (Figure 3C).
After protein quantification, we compared the value
obtained for each sample and each protein with the
respective standard curve to ensure correct measurement.
The limit of quantitation was set as signal-to-noise ratio of
10:1 in accordance with the guidelines from the European
Directorate for the Quality of Medicine set out in the
European Union Pharmacopoeia.8
The results of Aiolos quantification in six samples are
shown in Figure 3D, in which virtual blots for both Aiolos
and GAPDH are presented. 
Analysis of mRNA and protein expression 
We analyzed the expression of 12 genes and their
encoded proteins, together with GAPDH as a control
(Figure 1). We decided to select proteins involved in MM
or cancer pathogenesis: Cyclin D1 and Cyclin D2, whose
overexpression is a unifying event for most MM;9–11 c-myc,
which is consistently found to be involved in the transfor-
mation of monoclonal gammopathy of undetermined sig-
nificance into MM;12,13 HSP90, which is upregulated in
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Table 1. Summary of proteins and antibodies used in the study.
             Target protein             Company                 Cat number         Species              Clonality        Dilution Ab          MW peak         Intra-assay CV (%)
1                     Aiolos                   Cell Signaling                       12720                  Rabbit                 Polyclonal               1:100                        85                                10.9
2                   Calnexin              Enzolifesciences              ADI-SPA-860            Rabbit                 Polyclonal               1:250                       119                                4.9
3                  Cereblon                    NovusBio                     NBP1-91810            Rabbit                 Polyclonal                1:80                         59                                 9.7
4                     c-myc                   Cell Signalling                        5605                   Rabbit               Monoclonal               1:50                         75                                 8.3
5                  Cyclin D1                       Abcam                          Ab134175              Rabbit               Monoclonal               1:50                         40                                 9.9
6                  Cyclin D2                Cell Signaling                        3741                   Rabbit               Monoclonal              1:100                        38                                 7.8
7                     DDX21                         Abcam                          Ab182156              Rabbit               Monoclonal              1:100                       110                               11.4
8                     HSP90                   Cell Signaling                        4877                   Rabbit               Monoclonal               1:50                         95                                 7.0
9                     Ikaros                      Santa Cruz                       Sc-13039               Rabbit                 Polyclonal                1:50                         70                                10.8
10                  PSME1                      NovusBio                     NBP1-83121            Rabbit                 Polyclonal                1:50                         37                                10.2
11                   RIPK1                   Cell Signaling                        3493                   Rabbit               Monoclonal               1:50                         79                                 5.8
12                    XAF1                    Cell Signaling                       13805                  Rabbit               Monoclonal               1:25                     46, 110                            15.5
13                  GAPDH                  Cell Signaling                        2118                   Rabbit               Monoclonal               1:50                         42                                 8.6
Ab: antibody; MW: molecular weight; CV: coefficient of variation.
many solid and hematologic malignancies, including
MM;14 Calnexin, which forms endoplasmic reticulum and
is upregulated in MM relative to normal plasma cells in
genetically identical twin samples;15 and DDX21 or RIPK1,
with known involvement in several tumors.16–18 In addi-
tion, proteins involved in the mechanism of action of
antimyeloma drugs were included: Cereblon, Ikaros,
Aiolos for immunomodulatory drugs; XAF1 for melpha-
lan; and PSME1 for bortezomib.19–22 
At the protein level, PSME1 and Calnexin showed the
highest median level of expression, while HSP90 was the
most strongly expressed mRNA (Figure 4A,B). Conversely,
proteins Cyclin D1, Cyclin D2 and c-myc had the lowest
median level of expression, and CRBN, RIPK1 and XAF1
were the least expressed mRNA. 
In general, the expression of mRNA was more homoge-
nous than that of proteins, as indicated by the higher coef-
ficients of variation for the latter (Figure 4C). In fact, the
coefficients of variation were significantly lower than
those for c-myc, DDX21, HSP90, IKZF1 and PSME1
mRNA than for their respective encoded proteins. The
highest variability in expression, both at the mRNA and
protein levels, was observed for CCND2/Cyclin D2 and
CCND1/Cyclin D1, as well as for c-myc protein. 
Next, we analyzed the correlation between the two lev-
els of gene expression, mRNA and protein. Interestingly,
Nano-scale protein quantification in multiple myeloma
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Figure 2. Optimization of protein extraction from RLT Plus samples. Due to the various additives in the sample buffer there is marked incompatibility with most of
the normally used protein quantification methods. The Total Protein assay was therefore used, as it is insensitive to high SDS concentrations. The standard curve was
generated using JJN3 cell line extracts at 0.25 mg/mL concentration, and serial dilutions thereof. Each capillary contained one sample of a known concentration.
Results were visualized as virtual gels (A) and the numbers correspond to the areas under the curves of the peaks (B). A standard curve was generated, plotting the
result for each capillary quantification (C). Amount of protein obtained from each sample (D). Comparison of results from Calnexin, Cyclin D2, GAPDH and Ikaros quan-
tification in the U266 cell line, from which protein extracts were obtained by RLT Plus and RIPA extraction, and visualized as virtual blots or two distinct dilutions of




only Cyclin D1 and Cyclin D2 protein levels were strongly
correlated with the respective CCND1 and CCND2mRNA
levels (Figure 4D). We observed a modest correlation for
Aiolos, Calnexin and DDX21 proteins with their respective
mRNA. 
Although the number of proteins analyzed was limited,
we examined the correlation between the levels of the dif-
ferent proteins. A positive correlation was observed
between most of the protein pairs (Online Supplementary
Figure S2). We confirmed the previously described relation-
ship between Ikaros/Aiolos and c-myc.19 Additionally, c-
myc protein expression was positively correlated with
Cereblon, Calnexin, and RIPK1, and negatively correlated
with DDX21 (Online Supplementary Figure S2). We found
that protein levels of Cereblon, Ikaros and Aiolos, all of
which are required for the activity of immunomodulatory
drugs, were correlated with each other (Online
Supplementary Figure S2). 
The potential association between the expression of pro-
teins and mRNA tested in the study and chromosomal
abnormalities was also explored. We confirmed the well-
established pattern of CCND1/Cyclin D1 and
CCND2/Cyclin D2 expression in t(11;14) and t(4;14)
(Online Supplementary Figure S3). A lower level of expression
of PSME1 and RIPK1 proteins in MM with 1q gains, and a
higher level of IKZF1 mRNA expression in MM with
t(11;14) were also observed.
Influence of mRNA and protein levels on survival 
of myeloma patients
Since clinical data were available for 43 MM patients, 24
enrolled in GEM 2010 and 19 in BenVelPres clinical trials,
we also performed survival analysis for proteins and
mRNA using PFS as the endpoint (Table 2). Cereblon and
Ikaros were the only proteins able to predict PFS.
Interestingly, mRNA levels of CRBN and IKZF1 were not
associated with prognosis (Figure 5). Accordingly, patients
with a high level of Cereblon protein had a longer PFS
than those with a low level (50.4 versus 16.3 months,
P<0.001). Similarly, high levels of Ikaros protein were
associated with longer PFS (45.1 versus 17.8 months,
P<0.01). The levels of two mRNA were associated with
longer PFS: a high level of PSME1 (50.4 versus 23.5
months, P<0.05) and a low level of XAF1 (20.3 versus 45.1
months, P<0.05). 
Since Cereblon, Ikaros and Aiolos are involved in the
mechanism of action of immunomodulatory drugs, and
only GEM2010 patients were treated with lenalidomide,
we examined whether the prognostic value of these pro-
teins was influenced by the type of treatment. Indeed,
high levels of Cereblon and Ikaros were both associated
with longer PFS only in patients who received
immunomodulatory drugs and not in those treated with
other drugs (Figure 6). 
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Figure 3. Optimization of protein expression quantification. For each protein the standard curve was generated using the sample with the strongest signal to prepare
the serial dilutions. Each dilution was run in a separate capillary. The sample result for Aiolos is visualized as a virtual blot (A) or as peaks (B). The standard curve
established the linear range for each protein (C). The sample result for Aiolos together with the respective GAPDH for each sample was run in separate capillaries




MM has been comprehensively studied at the DNA and
RNA levels using high-throughput technologies such as
microarrays for detecting copy number abnormalities, and
gene expression profiling, and, more recently, next-gener-
ation sequencing for DNA mutation analysis. MM sam-
ples after CD138+ separation are usually stored in buffers
such as TRIZOL or RLT Plus, which preserve nucleic acids
for subsequent use in genomic studies. While it is techni-
cally possible to extract proteins from these buffers,23–25 the
quantity of protein would not be sufficient for multiple
WB to be carried out. In the classic WB, the amount of the
purified plasma cells, even if all of it were available for the
Nano-scale protein quantification in multiple myeloma
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Figure 4. Two levels of analysis of each gene RNA and protein. mRNA expression of each gene was assessed by qRT-PCR and normalized relative to GAPDH and
expressed as 2-ΔCt (A). Abundance of each protein was assessed by CNIA and normalized relative to GAPDH abundance in each case (B). The Y axis of graphs (A) and
(B) are expressed on a log scale. The variability of each mRNA and protein measurement in the analyzed population of patients with MM, measured as percentage
coeffcient of variation (CV%). The threshold of statistical significance (*P<0.05) was determined as described in the Methods section (C). Spearman correlation coef-




protein studies, would have allowed at most six proteins
to be evaluated, the median amount of sample being suf-
ficient to analyze two proteins.
Here we present for the first time a method for quanti-
fying the expression of multiple proteins from myeloma
cells stored in the buffer commonly used for nucleic acid
preservation and isolation. We report a protocol for pro-
tein extraction from MM cells stored in RLT Plus buffer
based on a well-known acetone precipitation proce-
dure.26,27 We decided to add NaCl to the sample before pre-
cipitation, since a greater inorganic salt content is known
to improve protein yield.28 After testing several types of
salts and concentrations, we chose the one with the best
performance. We also assessed several methods of protein
pellet dissolution, finally settling for a 0.2 M NaOH and 4x
WB sample buffer, since slight changes in the pH of the
environment change protein solubility.26,29
In contrast to the classic WB, which provides only semi-
quantitative (blot-based) results, CNIA quantifies the area
under the curve of the signal in each capillary, enabling
expression relative to the control protein to be calculat-
ed.3,30 To determine whether the CNIA method is suitable
for evaluating the expression of multiple proteins, using
various antibodies, we tested the performance of each
protein in the WESTM system. We first optimized the con-
centration of the antibody to be employed using RIPA-
extracted proteins from MM cell lines, as suggested by the
system provider. The antibody dilution used has to be the
one that saturates the epitope-antibody binding, so that
the additional increase in antibody concentration would
not have caused the increase in the signal. Although the
concentration of antibodies used by the CNIA platform is
higher than that used in WB, lower amounts of antibody
are required because of the small volume of antibody.
Comparing the signal detected by each antibody when
the sample was extracted by the RIPA method with that
obtained using our protocol revealed no significant differ-
ences for any of the proteins evaluated, which supports
the suitability of the present protocol for extracting pro-
teins from RLT Plus buffer. We observed differences
between the predicted molecular weight and that detected
by the CNIA system for some proteins, regardless of the
extraction method. The most probable explanation for
this phenomenon is that migration depends on the mobil-
ity in the matrix.31 In fact, each system provides a unique
molecular weight value that depends on the particular
interactions between the matrix and protein, and the true
molecular weight can only be determined by mass spec-
trometry or sequencing.32 In our assay, we analyzed only
the data obtained from the antibodies that detected peaks
whose signal intensity was linear in the serial dilutions,
enabling the frequent biases in WB to be eliminated.
Although such standard curves are not usually calculated
as part of the WB method, this is highly recommendable.33
Even though, at first glance, the optimization step
required for each antibody seems laborious, one CNIA run
allows 24 samples to be analyzed, so it would be possible
to optimize, for example, four antibodies in 3 hours.
Therefore, bearing in mind the subsequent possibility of
quantifying protein abundances, it is not such a time-con-
suming process. 
After demonstrating that our approach accurately quan-
I. Misiewicz-Krzeminska et al.
886 haematologica | 2018; 103(5)
Table 2. Univariate analysis of progression-free survival.
mRNA              HR         Group         n       Median PFS (months)   P-value      Protein           HR           Group        n    Median PFS (months)     P-value
                       (CI)                                                                                                                                    (CI)
IKZF3                 1.84              H               10                         21.7                         0.19             Aiolos              0.51                  H             33                     45.1                           0.16
                       (0.74-4.6)         L               33                         45.1                                                               (0.19-1.34)            L             10                     23.5
CANX1                0.44              H               21                         50.4                        0.074         Calnexin           1.82                  H             22                       30                             0.2
                      (0.18-1.11)        L               22                         23.5                                                                (0.72-4.6)             L             18                     43.8
CRBN                 0.49              H               10                         50.4                         0.24          Cereblon           0.23                  H             31                     50.4                     0.00034
                      (0.14-1.67)        L               33                         29.8                                                               (0.09-0.55)            L             12                     16.3
CCND1               2.55              H               27                         29.8                        0.066         CyclinD1           1.55                  H             23                       30                            0.33
                      (0.91-7.14)        L               16                          NR                                                                (0.64-3.78)            L             20                      NR
CCND2               0.38              H               17                          NR                        0.053         CyclinD2           0.24                  H             11                      NR                          0.051
                      (0.13-1.05)        L               26                         29.8                                                               (0.05-1.03)            L             32                     29.8
MYC                   1.54              H               33                           30                          0.44             c-myc              0.63                  H             27                     45.1                           0.31
                      (0.51-4.64)        L               10                         45.1                                                               (0.26-1.56)            L             13                     29.8
DDX21                0.49              H               29                         43.8                          0.1              Ddx21              0.47                  H             14                     50.4                           0.18
                       (0.2-1.17)         L               14                         23.5                                                               (0.15-1.46)            L             23                       30
HSP90                0.52              H               24                         50.4                         0.14             Hsp90               1.5                   H             12                     29.8                           0.44
                      (0.22-1.25)        L               19                         23.5                                                               (0.53-4.27)            L             25                     50.4
IKZF1                 1.93              H               25                         29.8                         0.15            Ikaros              0.31                  H             32                     45.1                       0.0075
                      (0.77-4.83)        L               18                         43.8                                                               (0.12-0.77)            L             11                     17.8
PSME1                0.33              H               18                         50.4                      0.018          Psme1             0.48                  H             30                     45.1                           0.13
                      (0.12-0.86)        L               25                         23.5                                                               (0.19-1.26)            L             10                     16.3
RIPK1                 0.52              H               28                         50.4                         0.13             Ripk1              1.41                  H             11                       30                            0.49
                      (0.22-1.24)        L               15                         23.5                                                               (0.53-3.73)            L             29                     45.1
XAF1                   2.39              H               11                         20.3                      0.048            Xaf1                1.56                  H             15                       30                            0.34
                       (0.98-5.8)         L               32                         45.1                                                               (0.63-3.85)            L             25                     45.1
HR: hazard ratio; CI: confidence interval; PFS: progression-free survival; H: high level; L: low level.
tified the proteins extracted at the same time as the DNA
and RNA from the RLT Plus buffer, we investigated the
applicability of the method to the analysis of the expres-
sion of key proteins in MM biology, such as D Cyclins, c-
myc, Cereblon, Ikaros, and Aiolos, among others. We also
wanted to compare protein expression with the corre-
sponding mRNA level, since many basic studies have
revealed that only 30-40% of protein abundance can be
explained by the mRNA level.34 Our results showed a
moderate or low correlation between mRNA and protein
levels of expression, and are consistent with the general
observation that ~60% of the variation in protein concen-
tration cannot be explained by measuring mRNA alone.34
We also observed that the mRNA level was less variable
than protein expression among MM patients for all the
mRNA and protein pairs analyzed. Indeed, protein abun-
dance is regulated by a variety of complex mechanisms,
such as post-transcriptional and post-translational modifi-
cations, and protein degradation regulation.34,35 By measur-
ing mRNA abundance, only the early steps in a long chain
of regulatory events are considered.36 However, the
mRNA level is still often employed as a proxy for protein
abundance, mostly because of the lack of appropriate
technology to quantify proteins quickly and efficiently. 
Our results reproduce the well-known pattern of
CCND1/Cyclin D1 and CCND2/Cyclin D2 expression in
MM with t(11;14) and t(4;14).9 We also found a correla-
tion between c-myc and Ikaros and Aiolos levels, analyz-
ing either mRNA or protein expression, consistent with
the previously demonstrated regulation of c-myc by
Ikaros and Aiolos in MM.19 Interestingly, the correlation
between Ikaros and Aiolos levels was stronger for the
protein than for the mRNA. To our knowledge, this is the
first time that the protein levels of c-myc, Ikaros and
Aiolos have been quantified and the relationship between
their expressions analyzed in MM. In T-cell acute lym-
phoblastic leukemia, for example, the levels of mRNA
encoding Ikaros and Aiolos were weakly, but significantly
correlated.37
Among the proteins included in our study, we observed
a significant association between protein level and PFS for
Cereblon and Ikaros, while this association was not
observed for the respective mRNA levels. Cereblon forms
an E3 ubiquitin ligase complex together with the damaged
DNA binding protein 1 (DDB1), Cullin4A (CUL4) and
Roc1. Immunomodulatory drugs, such as lenalidomide or
pomalidomide, bind to Cereblon in a region located at the
C-terminus of this protein.38,39 Our results did not demon-
strate a correlation between Cereblon protein and mRNA
level, and showed that only high levels of Cereblon pro-
tein were associated with a good prognosis in MM. These
findings are concordant with those of previous studies and
support the usage of protein expression to evaluate
Cereblon levels.40
Several independent groups have identified Ikaros and
Aiolos as the downstream targets of Cereblon after
immunomodulatory drug activation.41–43 The role of the
level of Ikaros in MM survival is controversial. When
Ikaros expression was investigated at the RNA level, a low
level of mRNA IKZF1 expression was associated with bet-
ter prognosis in newly diagnosed patients treated with
immunomodulatory drugs.44 On the other hand, low
IKZF1 levels were found to predict a lack of responsive-
ness to immunomodulatory drugs and a shorter overall
survival in refractory MM patients.45 We observed that a
high level of Ikaros protein was associated with longer
PFS, while no significant impact on prognosis was
observed when PFS was estimated from mRNA levels.
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Figure 5. Progression-free sur-
vival according to levels of
MRNA and protein expression.
Progression-free survival in
patients with low and high lev-
els of mRNA (A) and protein (B)
expression. The log-rank test
was performed for each gene
and protein and Kaplan-Meier
curves represent the PFS of
MM patients depending on
mRNA and protein status.
Cutoff Finder software
(http://molpath.charite.de/cut
off) was used to obtain the
optimal cutoff, which was
defined as that producing the
most significant split that dis-
criminates between good and
poor survival by examining all
the possible cutoffs using the
log-rank test.
A B
These results are consistent with the longer survival dis-
played by relapsed/refractory MM patients treated with
lenalidomide who expressed high levels of IKZF1/3 pro-
tein, as evaluated by immunohistochemical staining.46
Although the number of patients analyzed in this
study is relatively small, the survival analysis carried out
dividing patients according to drug therapy showed that
high levels of Cereblon and Ikaros proteins are associat-
ed with a longer PFS only in patients who receive
immunomodulatory drugs and not in those who are
treated with other drugs. Other studies reached the same
conclusion that the level of Cereblon can predict the out-
come of patients with MM mainly in those treated with
immunomodulatory drugs.47–50 By contrast, in the present
series of MM patients, the level of Aiolos did not influ-
ence the outcome of the patients treated with
immunomodulatory drugs. 
In summary, we present the implementation of a novel
technique based on capillary nano-immunoassay for
quantifying protein expression in MM samples in the clin-
ical setting. The requirement for only a relatively small
amount of material means that, for the first time, more
than 20 proteins can be analyzed using the same sample
frozen for DNA and RNA analysis. This makes the CNIA
platform a fast, effective and accurate tool for exploring
the impact of different proteins on the survival of patients
with MM and for investigating new protein biomarkers
that could help to predict the response to new drugs that
directly target specific proteins. These encouraging results
require further validation in a larger cohort of patients
with MM or other hematologic malignancies. 
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Figure 6. Progression-free sur-
vival in patients with low and
high Cereblon, Aiolos and
Ikaros protein levels, depend-
ing on the treatment scheme
(only patients treated accord-
ing to GEM2010 trial received
lenalidomide). The log-rank
test was performed for each
protein and Kaplan-Meier
curves represent progression-
free survival of MM patients
depending on protein status.
Cutoff Finder software
(http://molpath.charite.de/cut
off) was used to obtain the
optimal cutoff, which was
defined as that producing the
most significant split that dis-
criminates between good and
poor survival by examining all
the possible cutoffs using the
log-rank test.
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